Mink Therapeutics Inc (INKT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $47.95M
Last updated: Nov 17, 2026 at 11:05 AM ET
Mink Therapeutics Inc (INKT) Competitors
The companies most similar to Mink Therapeutics are INmune Bio (INMB), NanoViricides (NNVC) and Nkarta (NKTX). By market cap, Mink Therapeutics ranks 7th of the 13 companies on this page; Immunic (IMUX) is the largest at $102.61M.
Peer Comparison
INKT's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Mink Therapeutics (INKT) | $47.95M | N/A | 236.3x | 0.0% | N/A | 0.0% | 0.00% |
| INmune Bio Inc (INMB) | $32.51M | N/A | N/A | 0.0% | N/A | 257.1% | 0.00% |
| NanoViricides Inc (NNVC) | $31.41M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Nkarta Inc (NKTX) | $85.23M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | $36.15M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Actinium Pharmaceuticals Inc (ATNM) | $51.56M | 4.1x | 1.3x | 32.2% | N/A | -100.0% | 0.00% |
| ImageneBio, Inc. (IMA) | $43.22M | N/A | 68.5x | 0.0% | N/A | 0.0% | 0.00% |
| Immunic Inc (IMUX) | $102.61M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Gain Therapeutics Inc (GANX) | $46.31M | N/A | N/A | 0.0% | -170.5% | -100.0% | 0.00% |
| iBio, Inc. Common Stock (IBIO) | $51.55M | N/A | 735.4x | 0.0% | N/A | 975.0% | 0.00% |
| NextCure Inc (NXTC) | $29.31M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| MAIA Biotechnology Inc. (MAIA) | $61.75M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| XBiotech Inc (XBIT) | $59.76M | N/A | N/A | 0.0% | N/A | -93.3% | 0.00% |
| Peer median | $48.93M | 4.1x | 68.5x | 0.0% | -170.5% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Mink Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| INmune Bio Inc (INMB) | INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease... | INMB competitors |
| NanoViricides Inc (NNVC) | NanoViricides, Inc., a nanobiopharmaceutical company, discovers, develops and markets drugs for the treatment of viral infections. | NNVC competitors |
| Nkarta Inc (NKTX) | Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. | NKTX competitors |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human... | TELO competitors |
| Actinium Pharmaceuticals Inc (ATNM) | Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplantation... | ATNM competitors |
| ImageneBio, Inc. (IMA) | ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. | IMA competitors |
| Immunic Inc (IMUX) | Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune... | IMUX competitors |
| Gain Therapeutics Inc (GANX) | Gain Therapeutics, Inc., a developing biotechnology company, is dedicated to developing a variety of therapies to treat diseases caused by protein misfolding. | GANX competitors |
| iBio, Inc. Common Stock (IBIO) | iBio, Inc., a biotech company, provides contract development and manufacturing services to outside partners and customers in the United States. | IBIO competitors |
| NextCure Inc (NXTC) | NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other... | NXTC competitors |
| MAIA Biotechnology Inc. (MAIA) | MAIA Biotechnology Inc. is an innovative biotechnology company focused on developing cutting-edge cancer therapies that significantly improve patient outcomes... | MAIA competitors |
| XBiotech Inc (XBIT) | XBiotech Inc., a biopharmaceutical company, discovers, develops and markets True Human monoclonal antibodies for the treatment of various diseases. | XBIT competitors |
Frequently Asked Questions About INKT
Who are Mink Therapeutics' main competitors?
The companies most similar to Mink Therapeutics include INmune Bio (INMB), NanoViricides (NNVC), Nkarta (NKTX), Telomir Pharmaceuticals, Inc. Common Stock (TELO) and Actinium Pharmaceuticals (ATNM), listed from the closest match.
Who is Mink Therapeutics' biggest competitor?
Immunic (IMUX) is the largest of the similar companies at $102.61M; INmune Bio (INMB) is the closest match by business profile, size, sector and industry.
How does INKT stock compare with its competitors?
INKT's P/S is 236.3x against a peer median of 68.5x; its net margin is 0.0% against a peer median of 0.0%.
Which of Mink Therapeutics' competitors pays a higher dividend?
Mink Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Mink Therapeutics bigger than its competitors?
No. Mink Therapeutics is 7th by market cap among the 13 companies on this page; the largest is Immunic (IMUX) at $102.61M.
INKT pages: Overview, Earnings, Forecast, Financials, Competitors